Aims: We evaluated the relationship between the ratios of eicosapentaenoic acid and arachidonic acid (EPA/AA), docosahexaenoic acid (DHA)/AA, and delta-5 desaturase activity (D5D) and atherogenic lipid profiles (ALP) and coronary atherosclerosis.

Methods: Polynsaturated fatty acids (PUFA) and ALP were assessed in 436 men with the first episode of acute coronary syndrome (ACS) not take any lipid-lowering drugs. D5D was estimated as the ratio of AA to dihomo-gamma-linolenic acid (DGLA). These biomarkers were compared between the lower and higher levels of EPA/AA (0.41) or DHA/AA (0.93) according to the levels in Japanese general population. The thrombolysis in myocardial infarction flow (TIMI) grade of the culprit coronary artery was visually estimated during the initial angiography.

Results: Approximately 70% of patients had low EPA/AA or DHA/AA. Serum levels of LDL-cholesterol, apolipoprotein B (apoB), and remnant lipoprotein cholesterol (RL-C) were significantly higher in the low EPA/AA or DHA/AA groups, while those of triglycerides and malondialdehyde-modified LDL (MDA-LDL) were significantly higher in the low EPA/AA group alone. The levels of EPA, EPA/AA, DHA/AA, and HbA1c increased and those of DGLA and apoA1 decreased with increasing number of stenotic vessels. Patients with three stenotic coronary vessels or TIMI grade ≥1 had significantly higher EPA levels compared with the others. The levels of LDL-cholesterol, non-HDL-cholesterol, triglycerides, small dense LDL-cholesterol, RL-C, MDA-LDL, apoB, and apoE decreased progressively and those of EPA, DHA, EPA/AA and HDL-cholesterol increased as D5D increased.

Conclusions: The EPA/AA is a superior risk marker than DHA/AA in term of correlation with ALP in ACS patients.

Key words: Eicosapentaenoic acid, Docosahexaenoic acid, Arachidonic acid, Delta-5, Acute coronary syndrome

Introduction

Numerous studies have demonstrated that n-3 polyunsaturated fatty acids (PUFA), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are present in fish oils, protect against cardiovascular diseases (CVDs), and the ratios of serum levels of EPA and DHA to arachidonic acid (AA, n-6 PUFA) have been recognized as promising risk markers for coronary artery disease (CAD)\(^1, 2\). Previous case-control studies including one study from our group\(^3\) have demonstrated that patients, especially younger ones, with both lower EPA/AA and DHA/AA had a greater probability of being acute coronary syndrome (ACS)\(^3, 4\) and/or ischemic stroke\(^5\). Other cross-sectional studies have demonstrated that EPA/AA but not DHA/AA was significantly associated with ACS\(^6, 7\). A cohort study of CAD patients...
underwent non-emergency percutaneous coronary intervention (PCI) found that lower EPA/AA (but not lower DHA/AA) was significantly associated with the incidence of major adverse cardiac events. However, between 20–80% of the patients in these studies were on statins; therefore, the relationships between these ratios and disease may have been influenced by drug use. A previous study of patients with CAD who underwent PCI demonstrated that pitavastatin (but not pravastatin) increased AA and reduced DHA without affecting EPA levels.

The Hisayama study, a population-based prospective cohort study of 3,103 community-dwelling Japanese men and women, aged ≥ 40 years, reported that the EPA/AA (but not the DHA/AA) was significantly inversely associated with the incidence of CAD in individuals with serum high sensitivity CRP (hsCRP) levels ≥ 1.0mg/L. However, there was no clear association of either ratio with CAD in the overall population. A recent report of the Hisayama study demonstrated that both EPA/AA and DHA/AA were significantly inversely associated with serum levels of resistin, an adipocyte-derived polypeptide associated with insulin resistance and subsequent atherosclerosis. Therefore, it remains unclear if one of these PUFA ratios is better than the other in predicting risk for CAD.

PUFA levels depend on dietary intake, bioavailability, and PUFA metabolism. In the biosynthesis of long chain PUFA from precursor PUFA, the crucial enzymes include elongase and desaturase. Delta-5 desaturase (Δ5D) and delta-6 desaturase (Δ6D) are two key enzymes in the synthesis of long-chain PUFA and are encoded by fatty acid desaturase 1 (FADS1) and FADS2 genes, respectively. Previous studies have reported that the FADS1 gene polymorphism (less function) was associated with increased CAD risk. Δ5D is involved in one step in the conversion of linoleic acid (LA, 18:2 n-6) and alpha-linolenic acid (ALA, 18:3 n-3) to AA (20:4 n-6) and EPA (20:5 n-3), respectively, as the sole enzymatic source of endogenous AA and EPA. EPA and DHA are strongly influenced by the dietary intake of pre-formed PUFA, and, while human can readily retroconvert DHA to EPA, the elongation of ALA to EPA and DHA is minimal. However, contrary results have also been very recently reported. The activities of Δ5D cannot be measured directly; generally, they are conventionally estimated from the ratio of AA to dihomo-gamma linolenic acid (DGLA, 20:3 n-6).
Serum apolipoprotein (apo) levels were determined using an immunoturbidimetric assay (Daichi Chemicals Co. Ltd. Tokyo, Japan). Malondialdehyde-modified LDL (MDA-LDL) levels were measured using an enzyme-linked immunosorbent assay. Lipoprotein(a) [Lp(a)] levels were measured using a latex agglutination immunoassay. Remnant lipoprotein cholesterol (RL-C) was measured using immunoprecipitation method using immunoaffinity mixed gel containing anti-apo A-I (apoA) and anti-apo B-100 (apoB) monoclonal antibodies, known as remnant-like particle cholesterol (RLP-C) (Japan Immunoresearch Laboratories, Takasaki, Japan) till March 31, 2016. Thereafter, they were measured using another homogenous assay, known as RemL-C (Kyowa Medex, Tokyo, Japan). Although the RLP-C and RemL-C were different, they have been reported to have significant positive correlation with each other, and we confirmed the correlation between each assay and PUFA as well (Supplementary Table 1). Serum samples were kept frozen at −80°C until the performing the assays for LDL-C and sdLDL-C that were measured using a direct homogenous assay. The kits used for the LDL-C and sdLDL-C tests were both provided by Denka Seiken. Non-HDL cholesterol (non-HDL-C) level was estimated by subtracting the HDL-C concentration from the T-C concentration. Large buoyant LDL (LbLDL-C) levels were estimated by subtracting the sdLDL-C concentration from the LDL-C concentration. The hsCRP level was measured using the Dade Behring BN assay. Plasma brain natriuretic peptide (BNP) levels were measured using chemiluminescence-enzyme immunoassay. The diagnosis of hypertension was based on a history of hypertension or blood pressure >140 mmHg systolic or >90 mmHg diastolic. Diabetes mellitus (DM) was diagnosed based on fasting serum glucose value ≥ 126 mg/dL, 2-hour glucose ≥ 200 mg/dL during an oral glucose tolerance test, random serum glucose ≥ 200 mg/dL, HbA1c ≥ 6.5%, or treatment with any hypoglycemic agents. Body mass index (BMI) was calculated as weight (kilograms) divided by height (meters) squared. Patients with a reported smoking history of at least one cigarette per day at admission were classified as current smokers. The extent of coronary vessel disease (VD) was classified according to the number of stenotic coronary vessels (1VD, 2VD and 3VD) which was defined as stenosis of 50% or greater narrowing of the diameter. The left ventricular ejection fraction (LVEF) were evaluated using the Simpson’s method using standard echocardiographic measurements within a few days of hospitalization.

**Statistical Analysis**

Statistical analyses were performed using SPSS Statistics for Macintosh, Version 23.0. The patients were classified based on EPA/AA ratio and DHA/AA ratio according to the general Japanese population from the Hisayama study. The median values of the serum EPA/AA ratio and DHA/AA ratio in Hisayama study were 0.41 and 0.93, respectively.

Categorical data are expressed as numbers and percentages, and differences were analyzed using chi-square tests. Normality of distribution was tested with Shapiro-Wilk tests. Differences in continuous variables between two groups were compared using the Mann-Whitney tests because a majority of the variables did not have Gaussian distribution. Comparisons between the quartiles of D5D activities were performed using Kruskal-Wallis tests when variables showed a non-normal distribution, and by one-way analysis of variance (ANOVA) with Tukey's honest significant difference test to identify differences between the groups. The correlations were analyzed using the Spearman tests. Age-adjusted logistic regression analysis was used to assess independent associations between FA and the presence of 3VD. All the statistical analyses were two tailed. P<0.05 was considered statistically significant.

**Results**

**Clinical Characteristics between High and Low EPA/AA or DHA/AA**

Table 1 and 2 summarize and compare the general characteristics and biomarkers between the participants with low and high EPA/AA and DHA/AA. Approximately 70% of patients with ACS were classified into the low EPA/AA and DHA/AA groups. Serum levels of LDL-C, non-HDL-C, RL-C, and apoB, and eGFR were significantly higher in the low EPA/AA and low DHA/AA groups, while serum levels of triglycerides, MDA-LDL, and hsCRP were significantly higher in only the low EPA/AA group. The serum BNP level was significantly higher in the high EPA/AA and low DHA/AA group. The serum levels of HDL-C, sdLDL-C, apoA-1, apoE, Lp(a), and HbA1c were comparable between the two groups.
Table 1. Comparison of clinical characteristics between low and high EPA/AA or DHA/AA

|                  | EPA/AA          | DHA/AA         |
|------------------|-----------------|----------------|
|                  | Low (n = 299)   | High (n = 137) |
| Age, years       | 62.5 ± 13.9     | 71.1 ± 10.5*** |
| BMI, kg/m²       | 24.4 ± 4.3      | 23.8 ± 3.6     |
| LVEF, %          | 50.3 ± 10.5     | 51.4 ± 10.7    |
| Risk factors     |                 |                |
| Hypertension, %  | 55.2            | 62.0           |
| Diabetes mellitus,% | 23.7         | 22.6           |
| Family History of CAD, % | 11.0     | 8.8            |
| Smoking (Current and Former), % | 85.3   | 74.5**         |
| Cardiovascular medication |             |                |
| Calcium Channel Blocker, % | 19.1         | 21.2           |
| ACE-I, %         | 1.7             | 2.2            |
| ARB, %           | 16.7            | 25.5*          |
| Beta-blocker, %  | 3.0             | 8.0*           |
| Antiplatelet, %  | 5.7             | 7.3            |

Data are presented as mean ± standard deviation or median (25% and 75% quartiles). Abbreviations are provided in the text. AA/DGLA is presented as estimated D5D. *p<0.05; **p<0.01; ***p<0.001 vs. low EPA/AA (<0.41) or low DHA/AA (<0.93). ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ARB, angiotensin II type 1 receptor blocker; BMI, body mass index; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Table 2. Comparison of various biomarkers between patients with low EPA/AA or DHA/AA and those with high EPA/AA or DHA/AA

|                  | EPA/AA          | DHA/AA         |
|------------------|-----------------|----------------|
|                  | Low (n = 299)   | High (n = 137) |
| EPA, µg/dl       | 41.0 ± 19.3     | 105.6 ± 51.1*** |
| DHA, µg/dl       | 114.5 ± 39.2    | 169.0 ± 44.6*** |
| AA, µg/dl        | 189.4 ± 58.6    | 155.3 ± 39.9*** |
| DGLA, µg/dl      | 41.2 ± 17.9     | 29.6 ± 21.3*** |
| AA/DGLA          | 5.05 ± 1.7      | 6.01 ± 2.08*** |
| LDL-C, mg/dL     | 131.7 ± 35.8    | 121.7 ± 32.6** |
| Non-HDL-C, mg/dL | 156.9 ± 42.0    | 145.8 ± 34.8** |
| HDL-C, mg/dL     | 44.2 ± 11.3     | 46.4 ± 12.1    |
| Triglycerides, mg/dL | 114.0 (71.0-175.0) | 95.0 (66.5-128.5)** |
| sdLDL-C, mg/dL   | 38.9 ± 21.1     | 35.8 ± 16.9    |
| RL-C, mg/dL      | 5.5 (3.4-9.0)   | 4.3 (3.0-6.1)** |
| MDA-LDL, mg/dL   | 148.7 ± 67.8    | 131.3 ± 48.4*  |
| ApoA1, mg/dL     | 118.6 ± 22.5    | 122.9 ± 25.4   |
| ApoB, mg/dL      | 106.2 ± 27.2    | 99.9 ± 24.2*   |
| ApoE, mg/dL      | 4.4 ± 1.6       | 4.1 ± 1.1      |
| Lp(a), mg/dL     | 17.3 ± 19.3     | 16.5 ± 19.0    |
| HbA1c, %         | 6.3 ± 1.4       | 6.1 ± 1.1      |
| eGFR, mL/min/1.73 m² | 74.4 ± 23.5   | 68.3 ± 22.8** |
| hsCRP, mg/dL     | 1.10 ± 2.70     | 0.74 ± 2.24*   |
| BNP, pg/mL       | 180.2 ± 334.4   | 186.4 ± 357.7* |

Data are presented as mean ± standard deviation or number (%). *p<0.05; **p<0.01; ***p<0.001 vs. low EPA/AA (<0.41) or low DHA/AA (<0.93). AA/DGLA is presented as estimated D5D. Not EPA, but either DHA, AA or DGLA was significantly directly associated with LDL-C, triglycerides, RL-C, and MDA-LDL, whereas PUFA was significantly inversely correlated with these biomarkers. Spearman correlation coefficients between PUFA and biomarkers were computed (Supplementary Table 2).
were significantly directly associated with non-HDL-C, sdLDL-C, apoB, and apoE. In contrast, (EPA + DHA) / AA was significantly and inversely associated with LDL-C, non-HDL-C, triglycerides, RL-C, and apoB.

Comparisons between the Severities of Coronary Lesions

The biomarkers were compared between the patients with and without TIMI0 (Table 3). Of the lipid biomarkers, only EPA was significantly lower in the TIMI0. The biomarkers were compared between three groups based on the number of stenotic coronary vessels (Table 4). The prevalence of TIMI0 gradually decreased with increasing number of stenotic vessels. Age and serum levels of EPA, EPA/AA, DHA/AA, HbA1c, and BNP gradually increased, while the prevalences of low EPA/AA and low DHA/AA, DGLA, apoB, and apoE decreased progressively from the lowest to the highest D5D quartile. Approximately, 55% and 60% of patients in the 3VD group were classified into the low EPA/AA and low DHA/AA groups, respectively. The Japanese dietary practices have markedly changed since the 1960s, and fish consumption is decreasing in the younger generation.

Comparisons between Quartiles According to the Estimated D5D Activities

Table 5 summarizes the levels of biomarkers between the four groups based on quartiles of D5D. The levels of EPA, DHA, EPA/AA, HDL-C and BNP increased progressively, while those of LDL-C, non-HDL-C, triglyceride, sdLDL-C, RL-C, MDA-LDL, apoB, and apoE decreased progressively from the lowest to the highest D5D quartile. In contrast, the prevalence of DM, HbA1c, DHA/AA, lbdLDL-C, and hsCRP did not differ between the quartiles of D5D. Multiple studies have demonstrated that decreased D5D is associated with insulin resistance, obesity, and incidence of DM.

| Table 3. Comparison of biomarkers between TIMI flow grade 0 and ≥ 1 on the initial coronary angiography |
|-------------------------------------------------|-------------------------------------------------|
| TIMI ≥ 1 (n = 193)                              | TIMI0 (n = 243)                                 |
| Age                                             |                                                 |
| EPA, µg/dl                                      | 64.7 ± 41.6                                    |
| DHA, µg/dl                                      | 135.1 ± 48.8                                   |
| AA, µg/dl                                       | 178.7 ± 58.5                                   |
| DGLA, µg/dl                                     | 35.5 ± 15.2                                    |
| EPA/AA                                          | 0.40 ± 0.30                                    |
| DHA/AA                                          | 0.81 ± 0.35                                    |
| AA/DGLA                                         | 5.54 ± 1.95                                    |
| LDL-C, mg/dL                                    | 126.3 ± 37.2                                   |
| Non-HDL-C, mg/dL                                | 150.7 ± 42.5                                   |
| HDL-C, mg/dL                                    | 46.2 ± 12.6                                    |
| Triglycerides, mg/dl                            | 109.0 ± (68.0-151.5)                           |
| sdLDL-C, mg/dL                                  | 36.2 ± 19.8                                    |
| RL-C, mg/dL                                     | 4.5 (3.2-7.4)                                   |
| MDA-LDL, mg/dL                                  | 141.6 ± 65.4                                   |
| ApoA1, mg/dL                                    | 122.4 ± 25.8                                   |
| ApoB, mg/dL                                     | 103.1 ± 27.8                                   |
| ApoE, mg/dL                                     | 4.2 ± 1.5                                      |
| Lp(a), mg/dL                                    | 17.5 ± 20.0                                    |
| HbA1c, %                                        | 6.3 ± 1.3                                      |
| eGFR, mL/min/1.73 m²                             | 74.1 ± 23.0                                    |
| hsCRP, mg/dL                                    | 1.03 ± 2.69                                    |
| BNP, pg/mL                                       | 210.3 ± 369.6                                  |

Data are presented as mean ± standard deviation or median (25% and 75% quartiles). Abbreviations are presented in the main text. AA/DGLA is presented as estimated D5D. *p < 0.05; **p < 0.01 using the Mann-Whitney tests.
other biomarkers were compared between obese and non-obese patients (Supplementary Table 5). Compared with non-obese patients, obese patients had significantly higher levels of AA, DGLA, LDL-C, non-HDL-C, triglyceride, sdLDL-C, RL-C, MDA-LDL, apoB, apoE, and HbA1c; significantly lower levels of DHA/AA, estimated D5D, HDL-C, and Lp(a); similar EPA/AA and lbLDL-C.

### Discussion

There are four novel findings in this report. First, according to the cutoff levels in the general Japanese population, levels of LDL-C, non-HDL-C, RL-C, and apoB were significantly higher in the low EPA/AA or low DHA/AA groups, while levels of triglycerides, MDA-LDL and hsCRP were significantly higher in the low EPA/AA group alone. Second, total thrombotic occlusion of coronary artery determined by TIMI0 was significantly associated with low EPA alone. Third, levels of EPA, EPA/AA, and DHA/AA were unexpectedly the highest in 3VD group, while more than half the patients were classified into low EPA/AA and DHA/AA groups. However, this result was not observed after adjusting for age. Fourth, levels of LDL-C, non-HDL-C, triglycerides, sdLDL-C, RL-C, MDA-LDL and apoB decreased progressively from the lowest to the highest D5D quartile. However, D5D activity was not associated with coronary atherosclerosis.

These results are in good agreement with those of previous reports that both EPA/AA and DHA/AA were positively associated with age at onset of ACS. In those studies, more than 15% of patients were on statins. A previous cross-sectional study with 507 patients (384 men) with acute ST elevation MI (STEMI) reported that levels of EPA, DHA, EPA/AA and DHA/AA were significantly lower in patients with 3VD and/or left main trunk disease (LMTD) than 2VD or 1VD. However, in that study, the blood samples were collected within 8 days of admission, and the mean LDL-C in 3VD/LMTD was 96.6 ± 31.6

---

**Table 4.** Comparisons of various biomarkers between the three groups based on the number of stenotic coronary arteries

|                  | 1VD (n = 206) | 2VD (n = 135) | 3VD (n = 95) |  
|------------------|---------------|---------------|--------------|
| Age              | 62.5 ± 13.7   | 66.4 ± 12.9*  | 69.4 ± 12.8*** |  
| TIMI 0, %        | 62.1          | 54.8          | 43.2         |  
| Low EPA/AA, %    | 75.2          | 68.1          | 54.7         |  
| Low DHA/AA, %    | 76.7          | 64.4          | 60.0         |  
| EPA, µg/dl       | 55.5 ± 35.6   | 64.2 ± 55.4   | 69.1 ± 42.7**  |  
| DHA, µg/dl       | 126.3 ± 43.7  | 136.4 ± 56.5  | 135.9 ± 43.5  |  
| AA, µg/dl        | 182.5 ± 54.4  | 173.2 ± 56.8  | 171.4 ± 56.9  |  
| DGLA, µg/dl      | 38.3 ± 15.6   | 37.8 ± 19.2   | 35.5 ± 27.3**  |  
| EPA/AA           | 0.33 ± 0.25   | 0.39 ± 0.41   | 0.44 ± 0.28**  |  
| DHA/AA           | 0.74 ± 0.30   | 0.81 ± 0.37*  | 0.86 ± 0.34**  |  
| AA/DGLA          | 5.23 ± 1.83   | 5.30 ± 1.86   | 5.68 ± 2.01   |  
| LDL-C, mg/dL     | 128.6 ± 34.4  | 130.3 ± 39.1  | 125.9 ± 30.5  |  
| Non-HDL-C, mg/dL | 153.4 ± 38.8  | 156.0 ± 42.7  | 150.0 ± 39.7  |  
| HDL-C, mg/dL     | 45.9 ± 11.6   | 44.3 ± 11.8   | 43.8 ± 11.3   |  
| Triglycerides, mg/dl | 108.5 (70.0-171.0) | 109.0 (70.0-157.0) | 108.0 (64.0-159.0) |  
| sdLDL-C, mg/dl   | 37.6 ± 19.1   | 40.2 ± 20.2   | 35.3 ± 21.0   |  
| RL-C, mg/dl      | 5.1 (3.3-8.9) | 5.1 (3.5-7.8) | 4.3 (3.0-7.7) |  
| MDA-LDL, mg/dL   | 142.2 ± 65.0  | 148.0 ± 61.4  | 138.7 ± 59.9  |  
| ApoA1, mg/dl     | 122.4 ± 21.5  | 118.4 ± 26.4* | 116.8 ± 22.9* |  
| ApoB, mg/dl      | 104.1 ± 24.9  | 105.4 ± 28.3  | 102.6 ± 27.0  |  
| ApoE, mg/dl      | 4.3 ± 1.4     | 4.4 ± 1.5     | 4.2 ± 1.7     |  
| Lp(a), mg/dl     | 17.3 ± 20.2   | 17.8 ± 18.3   | 15.7 ± 18.2   |  
| HbA1c, %         | 6.1 ± 1.1     | 6.4 ± 1.5     | 6.5 ± 1.4**   |  
| eGFR, mL/min/1.73 m² | 74.6 ± 23.3   | 71.4 ± 22.8   | 69.2 ± 24.4   |  
| hsCRP, mg/dL     | 0.86 ± 2.45   | 1.03 ± 2.41   | 1.19 ± 3.03   |  
| BNP, pg/mL       | 146.8 ± 309.5 | 189.2 ± 283.7**  | 248.6 ± 456.7**  |  

Data are expressed as mean ± standard deviation or median (25% and 75% quartiles). AA/DGLA is presented as estimated D5D. # Comparisons between the three groups were performed using Kruskal-Wallis tests. Abbreviations are provided in the main text. *p < 0.05, **p < 0.01, ***p < 0.001 vs. 1VD, using the Mann-Whitney tests.
These findings suggest that a majority of those patients were on statins. In contrast, LDL-C level in the patients with 3VD in this study was 125.9 ± 30.5 mg/dL and none of the patients were on any lipid-lowering agents. Therefore, these differences might have caused discrepancies in the results. Additionally, positive association of EPA, EPA/AA and DHA/AA with the presence of 3VD could not be observed after adjusting for age. Therefore, higher levels of EPA, EPA/AA and DHA/AA may solely reflect the higher number of elder patients with 3VD.

According to intravascular imaging studies such as optical coherence tomography (OCT) and intravascular ultrasound (IVUS), the coronary thrombus is mostly occlusive and sustained in STEMI, whereas it is usually incomplete and dynamic, or absent in unstable angina and non–STEMI. The former occlusive thrombus is associated with plaque rupture that is associated with thin-cap fibroatheromas, whereas the latter is associated with plaque erosion. However, these studies included few patients with ACS with TIMI0. Silent plaque ruptures and erosions with subsequent plaque healing plays an important role in the plaque growth and the development of coronary stenosis. A previous study demonstrated that low serum EPA was associated with lipid-rich plaque as evaluated using integrated backscatter IVUS in patients with CAD. A randomized controlled trial to compare open-label addition of 1.86g EPA and 1.5g DHA for 30 months in 218 patients with stable CAD treated with statins reported that higher plasma omega-3 PUFA index—calculated as (EPA + DHA) / total fatty acids (≥ 4%)—prevented the progression of coronary plaque volume in non-diabetic patients compared with lower omega-3 index (< 3.4%). A recent retrospective analysis in 60 patients with CAD reported that EPA therapy was associated with coronary plaque stability, which is defined as lower lipid index, lower macrophage grade, or higher minimum fibrous cap thickness determined by optical frequency domain imaging. Another previous study suggested that the incorporation of EPA into platelet membranes might reduce

### Table 5. Comparisons of various biomarkers between the quartiles of D5D estimated by AA/DGLA

| AA/DGLA | Q1 (n = 109) | Q2 (n = 109) | Q3 (n = 109) | Q4 (n = 109) | P |
|---------|-------------|-------------|-------------|-------------|---|
| Age, years | 60.8 ± 14.1 | 65.6 ± 12.9 | 66.3 ± 13.3 | 68.2 ± 12.9 | 0.001 |
| BMI, kg/m² | 25.7 ± 4.9 | 24.0 ± 3.3 | 24.1 ± 4.2 | 23.0 ± 3.5 | < 0.001 |
| LVEF, % | 51.5 ± 8.8 | 50.3 ± 9.6 | 50.4 ± 11.8 | 50.1 ± 11.8 | 0.748 |
| Prevalence of DM, % | 22.0 | 29.4 | 22.9 | 19.3 | 0.353 |
| Hba1c, % | 6.3 ± 1.2 | 6.2 ± 1.0 | 6.3 ± 1.3 | 6.3 ± 1.6 | 0.597 |
| EPA, μg/dl | 44.5 ± 22.9 | 57.8 ± 37.5 * | 61.8 ± 38.1 * | 80.5 ± 62.2 * * | < 0.001 |
| DHA, μg/dl | 119.0 ± 44.5 | 130.3 ± 49.9 | 130.5 ± 41.6 | 146.2 ± 52.4 * | 0.001 |
| EPA/AA | 0.27 ± 0.18 | 0.36 ± 0.28 * | 0.37 ± 0.26 * | 0.48 ± 0.45 * | < 0.001 |
| DHA/AA | 0.72 ± 0.30 | 0.80 ± 0.33 | 0.78 ± 0.30 | 0.85 ± 0.39 | 0.049 |
| LDL-C, mg/dL | 138.9 ± 32.3 | 127.3 ± 34.0 | 124.2 ± 37.6 * | 123.8 ± 34.8 * | 0.005 |
| lbLDL-C, mg/dL | 90.9 ± 26.9 | 88.4 ± 27.4 | 88.9 ± 30.2 | 91.2 ± 28.8 | 0.757 |
| sdLDL-C, mg/dL | 46.6 ± 23.0 | 38.7 ± 18.5 * | 34.3 ± 18.9 * | 32.3 ± 15.8 * * | < 0.001 |
| Non-HDL-C, mg/dL | 168.6 ± 41.3 | 152.3 ± 37.5 * | 147.9 ± 41.5 * | 144.9 ± 36.7 * | < 0.001 |
| HDL-C, mg/dL | 41.7 ± 9.0 | 43.9 ± 10.2 | 45.9 ± 13.9 * | 48.2 ± 11.9 * * | 0.001 |
| Triglycerides, mg/dL | 148.0 (93.3-213.8) | 112.0 (66.5-170.0) * | 101.0 (65.0-153.0) * | 87.0 (60.0-119.5) * * * | < 0.001 |
| RL-C, mg/dL | 7.0 (4.1-11.0) | 5.4 (3.3-8.2) | 4.8 (3.2-7.9) * | 4.1 (3.0-5.5) * * | < 0.001 |
| MDA-LDL, mg/dL | 167.5 ± 75.3 | 143.4 ± 54.6 * | 132.2 ± 53.6 * | 130.1 ± 59.4 * | < 0.001 |
| ApoA1, mg/dL | 118.3 ± 18.9 | 118.3 ± 22.0 | 120.0 ± 25.8 | 123.2 ± 26.5 | 0.478 |
| ApoB, mg/dL | 114.3 ± 25.0 | 101.9 ± 26.0 * | 100.9 ± 27.9 * | 99.8 ± 24.6 * | < 0.001 |
| ApoE, mg/dL | 4.9 ± 2.1 | 4.2 ± 1.3 * | 4.1 ± 1.2 * | 4.0 ± 0.9 * | 0.001 |
| Lp(a), mg/dL | 17.8 ± 18.8 | 16.6 ± 18.3 | 17.1 ± 21.0 | 16.9 ± 18.8 | 0.856 |
| eGFR, mL/min/1.73 m² | 75.1 ± 21.4 | 73.9 ± 22.4 | 72.4 ± 25.6 | 68.3 ± 24.0 | 0.233 |
| hsCRP, mg/dL | 0.59 ± 1.37 | 1.00 ± 2.92 | 1.02 ± 2.57 | 1.33 ± 3.06 | 0.932 |
| BNP, pg/mL | 94.2 ± 165.9 | 131.1 ± 185.5 | 197.4 ± 356.0 * | 306.3 ± 504.1 * * | < 0.001 |

Data are expressed as means ± standard deviation, median (25% and 75% quartiles) or number (%). Abbreviations are presented in the main text. Kruskal-Wallis tests and analysis of variance (ANOVA) with Tukey’s honest significant difference test was used to identify the differences between the groups. Q1: AA/DGLA < 4.03, Q2: 4.04 ≤ AA/DGLA < 5.07, Q3: 5.08 ≤ AA/DGLA < 6.29, Q4: AA/DGLA ≥ 6.29. *p < 0.05 vs Q1, **p < 0.05 vs Q2, ***p < 0.05 vs Q3 using Tukey-Kramer post-hoc test.
platelet aggregation through the formation of prostaglandin H3, which is then converted into prostaglandin I3 and thromboxane A3. In patients with DM, hyperlipidemia, and high levels of angiopoietin-2, a 6-month treatment with 1.8g EPA significantly decreased platelet-derived microparticles and sE-selectin. We speculated that high EPA might limit the size of the overlying thrombus and protect totally occlusive thrombus formation in coronary arteries, which will result in silent progression of coronary atherosclerosis till 3VD and advanced age. Future studies are required to evaluate the association between PUFA and coronary morphology such as ruptured or erosive plaque and healing lesion in patients with ACS.

D5D plays an important role in the production of both EPA and AA. Alterations in D5D activity have been reported to be associated with the risk of CVD. In a Swedish population-based prospective cohort study of 2,009 50-year old men, D5D was reported to have an inverse correlation with CVD mortality over a follow-up of 30 years. Their group reported that a diet rich in saturated fats decreased D5D. An euglycemic insulin clamp study in 264 American adolescents (average age: 15 years) demonstrated that D5D was inversely related to serum levels of triglycerides and fasting insulin whereas it had no association with BMI and serum levels of glucose, LDL-C and HDL-C. Another study reported that lower D5D was associated with obesity. In the present study, D5D was significantly lower in obese patients, while the incidence of DM and HbA1c levels were comparable between the D5D quartiles. We previously reported that impaired glucose tolerance and DM were far more common than normal glucose regulation in patients with ACS, even though their HbA1c levels remain within the normal range. In contrast to the general population, an association between D5D and incidence of DM may not be detected in patients with ACS. The present study is the first to demonstrate the markedly inverse association of serum LDL-C, especially sdLDL-C, non-HDL-C, triglycerides, MDA-LDL, RL-C, and apoB, and levels of the D5D. These findings suggest that decreased biosynthesis of long-chain PUFA were clearly associated with impaired metabolism of triglyceride-rich apoB-containing lipoproteins that are known as atherogenic lipid profiles (ALP). D5D were significantly associated with serum levels of EPA, DHA, and AA. According to a meta-analysis of prospective cohort studies investigating plasma PUFA and CAD outcome, the relative risk and 95% of confidence interval (CI) for CAD for EPA, DHA and AA were 0.78 (CI 0.65-0.94), 0.79 (CI 0.67-0.93), and 0.83 (CI 0.74-0.92), respectively. Therefore, it is conceivable that lower D5D is associated with CAD. However, the present results fail to demonstrate any association between D5D and coronary atherosclerosis. EPA and AA competed for D5D; however, the mechanisms underlying the positive association between EPA/AA and D5D remain to be determined. Additionally, it remains unclear why only EPA is associated with TIMI0. Further studies are needed to clarify the association between metabolism of PUFA or ALP and culprit coronary lesions.

The present study has several limitations. A major limitation is the single center cross-sectional analysis of only patients with ACS. Like with all cross-sectional studies, causal relationships cannot be established based on this design. Second, we used plasma concentrations of PUFA and not their compositions in non-fasting samples, and did not investigate the intake of PUFA from the last meal. Third, we could not measure PUFA in erythrocyte membranes and/or lipoprotein fractions. Fourth, D6D and stearoyl-CoA desaturase-1, another crucial enzyme of PUFA metabolism, were not investigated. Fifth, genetic variations in FADS1 were not measured. These factors should be investigated in future studies. Multiple studies have demonstrated that EPA and DHA have different effects on cardiometabolic risk factors. The present results demonstrated that EPA/AA is a superior risk marker in assessing ALP than DHA/AA.

Conflict of Interest
The authors have no conflicts to declare.

Financial Support
This study was supported by JSPS KAKENHI (Grant Number JP26460779, SK), and Research Grants from the Ito Foundation (SK).

Author Contributions
KA composed the article and conducted data analysis, data interpretation, and critical revision of the article. SK composed the article, conducted data analysis, contributed to the study design, data interpretation, and critical revision of the article. YY, FT, and MS contributed to acquisition of data and data analysis. HT, SK and ST contributed to acquisition of data, TS contributed to data interpretation and critical revision of the article.

Acknowledgments
We are grateful for the valuable help provided to...
this study by the nursing stuff of the catheterization laboratory and all the cardiologists at the Department of Cardiology of Showa University Hospital. We also gratefully acknowledge the critical advice of Dr. William S Harris, Department of Medicine, University of South Dakota School of Medicine, USA. We would like to thank Editage (www.editage.com) for English language editing.

References

1) Superko HR, Superko SM, Nasir K, Agatston A and Garrett BC: Omega-3 fatty acid blood levels: clinical significance and controversy. Circulation, 2013; 128: 2154-2161

2) Watanabe Y and Tatsuno I: Omega-3 polyunsaturated fatty acids for cardiovascular diseases: present, past and future. Expert Rev Clin Pharmacol, 2017; 10: 865-873

3) Koba S, Takao T, Shimizu F, Ogawa M, Ishii Y, Yokota Y, Furuyama F, Tsuoda F, Shoji M, Harris WS and Takada A: Comparison of plasma levels of different species of trans fatty acids in Japanese male patients with acute coronary syndrome versus healthy men. Atherosclerosis, 2019; 284: 173-180

4) Yagi S, Aihara K-i, Fukuda D, Takashima A, Bando M, Hara T, Nishimoto S, Ise T, Kusunose K, Yamaguchi K, Tobiume T, Iwase T, Yamada H, Soeki T, Wakatsuki T, Shimabukuro M, Akaike M and Sata M: Reduced ratio of eicosapentaenoic acid and docosahexaenoic acid to arachidonic acid is associated with early onset of acute coronary syndrome. Nutrition Journal, 2015; 14: 111-111

5) Ueno Y, Tanaka R, Yamashiro K, Miyamoto N, Hira K, Kurita N, Sakurai M, Urabe T, Shimada K, Miyazaki T, Daida H and Hattori N: Age Stratification and Impact of Eicosapentaenoic Acid and Docosahexaenoic Acid to Arachidonic Acid Ratios in Ischemic Stroke Patients. J Atheroscler Thromb, 2018; 25: 593-605

6) Nishizaki Y, Shimada K, Tani S, Ogawa T, Ando J, Takahashi M, Yamamoto M, Shinozaki T, Miyauchi K, Nagao K, Hirayama A, Yoshimura M, Komuro I, Nagai R and Daida H: Significance of imbalance in the ratio of serum n-3 to n-6 polyunsaturated fatty acids in patients with acute coronary syndrome. Am J Cardiol, 2014; 113: 441-445

7) Iwamatsu K, Abe S, Nishida H, Kagayama M, Nasuno T, Sakuma M, Toyota S and Inoue T: Which has the stronger impact on coronary artery disease, eicosapentaenoic acid or docosahexaenoic acid? Hypertension Research, 2016; 39: 272-275

8) Domei T, Yokoi H, Kuramitsu S, Soga Y, Arita T, Ando K, Shirai S, Kondo K, Sakai K, Goya M, Iwabuchi M, Ueeda M and Nobuyoshi M: Ratio of serum n-3 to n-6 polyunsaturated fatty acids and the incidence of major adverse cardiac events in patients undergoing percutaneous coronary intervention. Circ J, 2012; 76: 423-429

9) Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Sato A, Nozato T, Miyake S, Takeyama Y, Morino Y, Yamauchi T, Muramatsu T, Hibi K, Terashima M and Michishita I: Effects of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis in statin-treated patients with coronary artery disease. Am J Cardiol, 2013; 111: 6-11

10) Ninomiya T, Nagata M, Hata J, Hirakawa Y, Ozawa M, Yoshida D, Ohara T, Kishimoto H, Mukai N, Fukuhara M, Kitazono T and Kiyohara Y: Association between ratio of serum eicosapentaenoic acid to arachidonic acid and risk of cardiovascular disease: the Hisayama Study. Atherosclerosis (Amsterdam), 2013; 231: 261-267

11) Higashioka M, Hirakawa Y, Kawamura R, Honda T, Hata J, Yoshida D, Takata Y, Kitazono T, Osawa H and Ninomiya T: Ratios of serum eicosapentaenoic acid to arachidonic acid and docosahexaenoic acid to arachidonic acid were inversely associated with serum resistin levels: The Hisayama Study. Journal of Diabetes Investigation, 2019;

12) Tosi F, Sartori F, Guarini P, Olivieri O and Martinelli N: Delta-5 and delta-6 desaturases: crucial enzymes in polyunsaturated fatty acid-related pathways with pleiotropic influences in health and disease. Adv Exp Med Biol, 2014; 824: 61-81

13) Lv X, Zhang Y, Rao S, Qiu J, Wang M, Luo X, Zuo X, Su D, Feng X, Yang Y, Ouyang P, Chen Y, Li X, Xiao Y and Ling W: Joint effects of genetic variants in multiple loci on the risk of coronary artery disease in Chinese Han subjects. Circ J, 2012; 76: 1987-1992

14) Liu F, Li Z, Lv X and Ma J: Dietary n-3 polyunsaturated fatty acid intakes modify the effect of genetic variation in fatty acid desaturase 1 on coronary artery disease. PLoS One, 2015; 10: e0121255

15) Arterburn LM, Hall EB and Oken H: Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr, 2006; 83: 1467S-1476S

16) Oscarsson J and Hurt Camejo E: Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review. Lipids in Health and Disease, 2017; 16: 149-149

17) Metherel A, Irfan M, Klingel S, Mutch D and Bazinet R: Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial. American Journal of Clinical Nutrition, 2019; 110: 823-831

18) Ebbesson SOE, Voruganti V, Higgins P, Fabsitz R, Ebbeson L, Laston S, Harris W, Kennish J, Umans B, Wang H, Devereux R, Okin P, Weissman N, MacCluer J, Umans J and Howard B: Fatty acids linked to cardiovascular mortality are associated with risk factors. International journal of circumpolhar health, 2015; 74: 28055-28055

19) Harris WS, Luo J, Pottala JV, Margolis KL, Espeland MA and Robinson JG: Red Blood Cell Fatty Acids and Incident Diabetes Mellitus in the Women's Health Initiative Memory Study. PLoS One, 2016; 11: e0147894

20) Tsurtutani Y, Inoue K, Sugisawa C, Saito J, Oamura M and Nishikawa T: Increased Serum Dihomo-gamma-linolenic Acid Levels Are Associated with Obesity, Body Fat Accumulation, and Insulin Resistance in Japanese Patients with Type 2 Diabetes. Intern Med, 2018; 57: 2929-2935

21) Yanagisawa N, Shimada K, Miyazaki T, Kume A, Kita-mura Y, Ichikawa R, Sato A, Nozato T, Miyake S, Oueda M and Nobuyoshi M: Ratio of serum n-3 to n-6 polyunsaturated fatty acids ratios on coronary atherosclerosis.
H, Fujii K, Mokuno H, Inoue N and Daida H: Polyunsaturated fatty acid levels of serum and red blood cells in apparently healthy Japanese subjects living in an urban area. J Atheroscler Thromb, 2010; 17: 285-294

22) Harris WS, Pottala JV, Varrel SA, Borowski JJ, Ward JN and McConnell JP: Erythrocyte omega-3 fatty acids increase and linoleic acid decreases with age: observations from 160,000 patients. Prostaglandins Leukot Essent Fatty Acids, 2013; 88: 257-263

23) Group TS: The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med, 1985; 312: 932-936

24) Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramato M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H and Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes S: International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Investig, 2012; 3: 39-40

25) Kotani K, Maekawa M, Kanno T, Kondo A, Toda N and Manabe M: Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta, 1994; 1215: 121-125

26) Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H and Campos E: Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clinica chimica acta, 1993; 223: 53-71

27) Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H, Irie T, Tanaka A, Yamashita S and Yamamura T: Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem, 2007; 53: 2128-2135

28) Masuda D and Yamashita S: Postprandial Hyperlipidemia and Remnant Lipoproteins. J Atheroscler Thromb, 2017; 24: 95-109

29) Hsu H, Hsu P, Cheng MH, Ito Y, Kanda E, Schaefer EJ and Ai M: Lipoprotein Subfractions and Glucose Homeostasis in Prediabetes and Diabetes in Taiwan. J Atheroscler Thromb, 2019; 26: 890-914

30) Ito Y, Fujimura M, Ohta M and Hirano T: Development of a homogeneous assay for measurement of small dense LDL cholesterol. Clin Chem, 2011; 57: 57-65

31) Roberts WL, Moutlon L, Law TC, Farrow G, Cooper-Anderson M, Savory J and Rifai N: Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem, 2001; 47: 418-425

32) Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, Ura N, Kiyohara Y, Moriyama T, Ando Y, Fujimoto S, Konta T, Yokoyama H, Makino H, Hishida A and Matsuo S: Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol, 2009; 13: 621-630

33) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y, Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A, Yamashita S, Committee for E and Clinical Management of A: Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984

34) Yokoyama S: Beneficial Effect of Retuning to “Japan Diet” for the Japanese. Journal of Atherosclerosis and Thrombosis, 2019; 26: 1-2

35) Hodge A, English D, O’Dea K, Sinclair A, Makrides M, Gibson R and Giles G: Plasma phospholipid and dietary fatty acids as predictors of type 2 diabetes: interpreting the role of linoleic acid. American Journal of Clinical Nutrition, 2007; 86: 189-197

36) Krachler B, Norberg M, Eriksson JW, Hallmans G, Johansson I, Vessby B, Weinehall L and Lindahl B: Fatty acid profile of the erythrocyte membrane preceding development of Type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis, 2008; 18: 503-510

37) Patel P, Sharp S, Jansen E, Luben R, Khaw K-T, Wareham N and Forouhi N: Fatty acids measured in plasma and erythrocyte-membrane phospholipids and derived by food-frequency questionnaire and the risk of new-onset type 2 diabetes: a pilot study in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort. American Journal of Clinical Nutrition, 2010; 92: 1214-1222

38) Kröger J and Schulze M: Recent insights into the relation of Δ5 desaturase and Δ6 desaturase activity to the development of type 2 diabetes. Current Opinion in Lipidology, 2012; 23: 4-10

39) Jacobs S, Schiller K, Jansen EHJM, Boeijing H, Schulze M and Kröger J: Evaluation of various biomarkers as potential mediators of the association between Δ5 desaturase, Δ6 desaturase, and stearoyl-CoA desaturase activity and incident type 2 diabetes in the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. American Journal of Clinical Nutrition, 2015; 102: 155-164

40) Shimada T, Kadota K, Eguchi H, Osakada K, Kuyama A, Ohya M, Miura K, Amano H, Kubo S, Ozaki M, Hyodo Y, Yoshino M, Miyake K, Kawase Y, Ohashi N, Otsuru S, Tasaka H, Habara S, Tada T, Tanaka H, Maruo T, Fuku Y, Katoh H, Fujii S, Goto T and Mitsudo K: Relationship between n-3 Polyunsaturated Fatty Acids and Extent of Vessel Disease in Patients with ST Elevation Myocardial Infarction. International Heart Journal, 2017; 58: 868-873

41) Yamamoto E, Yonetsu T, Kakuta T, Soeda T, Saito Y, Yan BP, Kurihara O, Takano M, Niccolli G, Higuma T, Kimura S, Minami Y, Ako J, Adriaenssens T, Boeder NF, Nef HM, Fracassi F, Sugiyama T, Lee H, Crea F, Kimura T, Fujimoto JG, Fuster V and Jang IK: Clinical and Laboratory Predictors for Plaque Erosion in Patients With Acute Coronary Syndromes. J Am Heart Assoc, 2019; 8: e012322

42) Jia H, Abtahian F, Aguirre AD, Lee S, Chia S, Lowe H, Kato K, Yonetsu T, Vergallo R, Hu S, Tian J, Lee H, Park SJ, Jang YS, Raffel OC, Mizuno K, Uemura S, Itoh T, Arai et al.
entaenoic acid (EPA) in atherosclerosis. Atherosclerosis, 2015; 242: 357-366
51) Warensjö E, Sundström J, Vessby B, Cederholm T and Risérus U: Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. American Journal of Clinical Nutrition, 2008; 88: 203-209
52) Warensjo E, Riserus U, Gustafsson IB, Mohsen R, Cederholm T and Vessby B: Effects of saturated and unsaturated fatty acids on estimated desaturase activities during a controlled dietary intervention. Nutr Metab Cardiovasc Dis, 2008; 18: 683-690
53) Steffen LM, Vessby B, Jacobs DR, Jr., Steinberger J, Moran A, Hong CP and Sinaiko AR: Serum phospholipid and cholesteryl ester fatty acids and estimated desaturase activities are related to overweight and cardiovascular risk factors in adolescents. Int J Obes (Lond), 2008; 32: 1297-1304
54) Ban Y, Koba S, Tsunoda F, Yokota Y, Ezumi H, Kondo T, Suzuki H and Katagiri T: Predominance of small dense low-density lipoproteins and abnormal glucose regulation in patients with acute coronary syndrome. Circ J, 2006; 70: 393-401
55) Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J and Di Angelantonio E: Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med, 2014; 160: 398-406
56) Innes JK and Calder PC: The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review. Int J Mol Sci, 2018; 19:

43) Libby P, Pasterkamp G, Crea F and Jang IK: Reassessing the Mechanisms of Acute Coronary Syndromes. Circ Res, 2019; 124: 150-160
44) Bentzon JF, Otsuka F, Virmani R and Falk E: Mechanisms of plaque formation and rupture. Circ Res, 2014; 114: 1852-1866
45) Amano T, Matsubara T, Uetani T, Kato M, Kato B, Yoshida T, Harada K, Kumagai S, Kunimura A, Shinbo Y, Kitagawa K, Ishii H and Murohara T: Impact of omega-3 polyunsaturated fatty acids on coronary plaque instability: an integrated backscatter intravascular ultrasound study. Atherosclerosis, 2011; 218: 110-116
46) Alfaddagh A, Elajami T, Saleh M, Mohebali D, Bistrian B and Welty F: An omega-3 fatty acid plasma index ≥ 4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment. Atherosclerosis (Amsterdam), 2019; 285: 153-162
47) Konishi T, Sunaga D, Funayama Y, Yamamoto T, Murakami H, Hotta D, Nojima M and Tanaka S: Eicosapentaenoic acid therapy is associated with decreased coronary plaque instability assessed using optical frequency domain imaging. Clinical Cardiology, 2019; 42: 618-628
48) Needleman P, Raz A, Minkes MS, Ferrendelli JA and Sprecher H: Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci U S A, 1979; 76: 944-948
49) Nomura S, Shouzu A, Omoto S, Inami N, Ueba T, Urase F and Maeda Y: Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J Atheroscler Thromb, 2009; 16: 83-90
50) Borow KM, Nelson JR and Mason RP: Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis, 2015; 242: 357-366
51) Warensjö E, Sundström J, Vessby B, Cederholm T and Risérus U: Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. American Journal of Clinical Nutrition, 2008; 88: 203-209
52) Warensjo E, Riserus U, Gustafsson IB, Mohsen R, Cederholm T and Vessby B: Effects of saturated and unsaturated fatty acids on estimated desaturase activities during a controlled dietary intervention. Nutr Metab Cardiovasc Dis, 2008; 18: 683-690
53) Steffen LM, Vessby B, Jacobs DR, Jr., Steinberger J, Moran A, Hong CP and Sinaiko AR: Serum phospholipid and cholesteryl ester fatty acids and estimated desaturase activities are related to overweight and cardiovascular risk factors in adolescents. Int J Obes (Lond), 2008; 32: 1297-1304
54) Ban Y, Koba S, Tsunoda F, Yokota Y, Ezumi H, Kondo T, Suzuki H and Katagiri T: Predominance of small dense low-density lipoproteins and abnormal glucose regulation in patients with acute coronary syndrome. Circ J, 2006; 70: 393-401
55) Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J and Di Angelantonio E: Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. Ann Intern Med, 2014; 160: 398-406
56) Innes JK and Calder PC: The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review. Int J Mol Sci, 2018; 19:
57) Tsunoda F, Lamon-Fava S, Asztalos BF, Iyer LK, Richardson K and Schaefer EJ: Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression. Atherosclerosis, 2015; 241: 400-408

Advance Publication Journal of Atherosclerosis and Thrombosis
Accepted for publication: April 6, 2020   Published online: June 27, 2020
Supplementary Table 1. The correlation between RLP-C assessed by Immnoprecipitation assay and RemL-C by homogenous assay and various biomarkers

| Biomarker                | Immnoprecipitation assay (n = 311) | Homogenous assay (n = 125) |
|-------------------------|------------------------------------|-----------------------------|
| BMI                     | 0.321**                            | 0.224*                      |
| LDL-C, mg/dL            | 0.382**                            | 0.409**                     |
| Non-HDL-C, mg/dL        | 0.613**                            | 0.606**                     |
| Triglyceride, mg/dL     | 0.819**                            | 0.910*                      |
| sdLDL-C, mg/dL          | 0.530**                            | 0.666**                     |
| Apo B, mg/dL            | 0.547**                            | 0.569**                     |
| Apo E, mg/dL            | 0.598**                            | 0.567**                     |
| EPA, µg/dl              | 0.010                              | 0.182*                      |
| DHA, µg/dl              | 0.207**                            | 0.297**                     |
| AA, µg/dl               | 0.502**                            | 0.379**                     |
| DGLA, µg/dl             | 0.563**                            | 0.599**                     |

Data are expressed as Spearman’s Rho between RL-C measured by different assays and various biomarkers. *p<0.05, **p<0.01

Supplementary Table 2. The correlation between PUFA and various biomarkers

| Biomarker                | EPA, µg/dl | DHA, µg/dl | AA, µg/dl | DGLA, µg/dl | (EPA + DHA)/AA |
|-------------------------|------------|------------|-----------|-------------|----------------|
| EPA, µg/dl              | 0.823**    | 0.823**    | 0.081     | -0.155**    | 0.010          |
| DHA, µg/dl              | 0.081      | 0.206*     | 0.206**   | 0.001       | 0.719**        |
| AA, µg/dl               | -0.155**   | 0.001      | 0.604**   | -0.442**    |                |
| DGLA, µg/dl             | 0.782**    | 0.719**    | -0.453**  | -0.442**    |                |
| (EPA + DHA)/AA          | 0.067      | 0.137**    | 0.451**   | 0.446**     | 0.169**        |
| LDL-C, mg/dL            | 0.127**    | 0.265**    | 0.571**   | 0.554**     | -0.151**       |
| Non-HDL-C, mg/dL        | 0.030      | 0.230**    | 0.394**   | 0.538**     | -0.115*        |
| HDL-C, mg/dL            | 0.013**    | 0.065      | 0.091     | -0.092      | 0.041          |
| Triglycerides, mg/dL    | 0.187**    | 0.319**    | 0.470**   | 0.556**     | 0.053          |
| Apo A1, mg/dL           | 0.056      | 0.225**    | 0.464**   | 0.562**     | -0.143**       |
| Apo B, mg/dL            | 0.061      | 0.219**    | 0.384**   | 0.486**     | -0.093         |
| Apo E, mg/dL            | 0.040      | 0.188**    | 0.287**   | 0.162**     | 0.001          |
| Lp(a), mg/dL            | 0.139**    | 0.295**    | 0.539**   | 0.527**     | -0.117*        |
| HbA1c, %                | 0.156**    | 0.348**    | 0.495**   | 0.474**     | -0.060         |
| BMI, kg/m²              | -0.002     | 0.012      | 0.014     | -0.034      | -0.013         |
|                         | -0.007     | 0.039      | 0.062     | 0.101*      | -0.016         |
|                         | 0.016      | -0.012     | 0.210**   | 0.325**     | -0.130**       |

Data are expressed as Spearman’s Rho between PUFA and various biomarkers. *p<0.05, **p<0.01
Supplementary Table 3. Comparisons of various biomarkers between the three groups based on the number of stenotic coronary arteries in elderly patients (≥ 60 years)

|                      | 1VD (n = 121) | 2VD (n = 92) | 3VD (n = 77) | P     |
|----------------------|--------------|--------------|--------------|-------|
| Age                  | 72.1 ± 8.1   | 73.3 ± 8.7   | 74.1 ± 8.4   | 0.199 |
| EPA, µg/dl           | 59.4 ± 37.2  | 67.8 ± 41.8  | 69.9 ± 39.2  | 0.094 |
| DHA, µg/dl           | 131.3 ± 44.7 | 143.4 ± 56.1 | 136.1 ± 42.1 | 0.288 |
| AA, µg/dl            | 163.0 ± 47.0 | 158.9 ± 39.9 | 157.0 ± 43.8 | 0.790 |
| DGLA, µg/dl          | 33.2 ± 12.5  | 31.3 ± 12.9  | 32.9 ± 27.8  | 0.156 |
| EPA/AA               | 0.38 ± 0.26  | 0.43 ± 0.28  | 0.47 ± 0.28* | 0.039 |
| DHA/AA               | 0.84 ± 0.31  | 0.92 ± 0.33  | 0.92 ± 0.33  | 0.084 |
| AA/DGLA              | 5.38 ± 1.96  | 5.57 ± 1.80  | 5.66 ± 1.96  | 0.226 |
| LDL-C, mg/dL         | 120.1 ± 31.3 | 119.8 ± 33.0 | 120.4 ± 29.1 | 0.889 |
| Non-HDL-C, mg/dL     | 142.1 ± 34.6 | 143.2 ± 33.6 | 140.7 ± 33.4 | 0.830 |
| HDL-C, mg/dL         | 47.0 ± 12.0  | 45.7 ± 12.7  | 44.3 ± 11.9  | 0.246 |
| Triglycerides, mg/dL | 93.0 (62.0-135.0) | 97.0 (66.0-125.8) | 95.0 (63.0-139.5) | 0.944 |
| sdLDL-C, mg/dL       | 32.9 ± 15.9  | 35.8 ± 16.2  | 31.5 ± 17.3  | 0.129 |
| RL-C, mg/dL          | 4.2 (3.1-6.6) | 4.3 (3.1-6.8) | 4.1 (2.9-7.0) | 0.548 |
| MDA-LDL, mg/dL       | 135.1 ± 65.4 | 132.8 ± 52.4 | 130.0 ± 55.4 | 0.859 |
| ApoA1, mg/dL         | 122.1 ± 22.8 | 120.0 ± 27.9 | 116.4 ± 24.5 | 0.153 |
| ApoB, mg/dL          | 97.4 ± 22.0  | 97.1 ± 23.5  | 96.9 ± 24.4  | 0.952 |
| ApoE, mg/dL          | 4.1 ± 1.1    | 4.0 ± 1.1    | 3.9 ± 0.9    | 0.776 |
| Lp(a), mg/dL         | 20.0 ± 21.0  | 17.0 ± 18.4  | 16.3 ± 18.0  | 0.584 |
| HbA1c, %             | 5.9 ± 1.4    | 6.4 ± 1.4*   | 6.2 ± 1.0*   | 0.035 |
| eGFR, mL/min/1.73 m² | 67.7 ± 22.7  | 66.4 ± 22.4  | 65.1 ± 22.1  | 0.760 |
| hsCRP, mg/dL         | 1.1 ± 3.01   | 0.83 ± 2.12  | 1.06 ± 2.74  | 0.805 |
| BNP, pg/mL           | 206.7 ± 376.5| 208.8 ± 287.6| 286.9 ± 494.7| 0.375 |

Data are expressed as mean ± standard deviation or median (25% and 75% quartiles). AA/DGLA is presented as estimated D5D. Comparisons between the three groups were performed using Kruskal-Wallis tests. Abbreviations are presented in the text. *p < 0.05 vs. 1VD using the Mann-Whitney tests.

Supplementary Table 4. Logistic regression analysis for the determination of the presence of 3VD

|               | Univariate |            | Age-adjusted |            |
|---------------|------------|------------|--------------|------------|
|               | OR         | p          | OR           | p          |
| Age           | 1.031      | 0.001      |              |            |
| EPA           | 1.005      | 0.06       | 1.004        | 0.096      |
| EPA/AA        | 2.100      | 0.037      | 1.692        | 0.125      |
| DHA/AA        | 2.085      | 0.026      | 1.434        | 0.317      |

OR, odds ratio
### Supplementary Table 5. Comparisons of biomarkers between obese (BMI ≥ 25 kg/m²) and non-obese (BMI < 25 kg/m²) patients

|                      | BMI < 25 (n = 277) | BMI ≥ 25 (n = 159) |
|----------------------|---------------------|---------------------|
| **Age**              | 68.4 ± 12.4         | 59.4 ± 13.5***     |
| **BMI, kg/m²**       | 21.9 ± 2.1          | 28.2 ± 3.7***      |
| **EPA, µg/dl**       | 62.8 ± 48.3         | 58.9 ± 36.6        |
| **DHA, µg/dl**       | 132.5 ± 47.7        | 130.3 ± 49.1       |
| **AA, µg/dl**        | 170.4 ± 48.6        | 194.1 ± 63.5***    |
| **DGLA, µg/dl**      | 33.8 ± 15.6         | 44.2 ± 24.2***     |
| **EPA/AA**           | 0.39 ± 0.34         | 0.33 ± 0.25        |
| **DHA/AA**           | 0.82 ± 0.34         | 0.72 ± 0.32**      |
| **AA/DGLA**          | 5.62 ± 1.97         | 4.89 ± 1.63***     |
| **LDL-C, mg/dL**     | 126.0 ± 34.8        | 133.5 ± 35.0*      |
| **Non-HDL-C, mg/dL** | 148.5 ± 37.8        | 162.8 ± 42.3**     |
| **HDL-C, mg/dL**     | 46.6 ± 11.9         | 42.0 ± 10.6***     |
| **Triglycerides, mg/dL** | 95.0 (63.3-141.0) | 132.5 (92.3-213.3)*** |
| **lbLDL-C, mg/dL**   | 90.5 ± 28.9         | 89.1 ± 27.3        |
| **sdLDL-C, mg/dL**   | 35.4 ± 17.7         | 42.5 ± 22.6**      |
| **RL-C, mg/dL**      | 4.4 (3.1-6.9)       | 6.5 (4.1-11.6)***  |
| **MDA-LDL, mg/dL**   | 139.5 ± 64.9        | 150.5 ± 58.3*      |
| **ApoA1, mg/dL**     | 121.5 ± 24.3        | 117.3 ± 21.9       |
| **ApoB, mg/dL**      | 101.1 ± 25.4        | 109.9 ± 27.0**     |
| **ApoE, mg/dL**      | 4.1 ± 1.2           | 4.7 ± 1.9***       |
| **Lp(a), mg/dL**     | 18.8 ± 20.0         | 14.2 ± 17.5**      |
| **HbA1c, %**         | 6.1 ± 1.2           | 6.5 ± 1.5*         |

Data are expressed as mean ± standard deviation or median (25% and 75% quartiles). AA/DGLA is presented as estimated D5D. *p < 0.05, **p < 0.01, ***p < 0.001 using the Mann-Whitney tests.